Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes,…The UP study – Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson’s disease
Objective: To determine the safety and tolerability of ursodeoxycholic acid (UDCA) in Parkinson’s disease (PD) and explore its neuroprotective potential. Background: We previously undertook the…NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson’s Disease: Exploratory Efficacy Outcomes
Objective: To report secondary and exploratory analysis of efficacy of nilotinib in moderate/advanced Parkinson’s disease (PD) participants enrolled in NILO-PD study. Background: Previously completed studies…A pooled analysis of four pivotal, randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: Efficacy as adjunct to levodopa in Parkinson’s disease (PD)
Objective: To determine the efficacy of istradefylline combined with levodopa in PD patients experiencing motor fluctuations in a pooled analysis of 4 pivotal, randomized, placebo-controlled…Effects of a community-based adapted boxing program on physical capacity and quality of life in individuals with Parkinson disease over a 12 month period
Objective: The main objective was to assess long-term effects of a community-based adapted boxing program on physical capacity and QoL in individuals with mild, or…Motor subtype change between OFF and ON periods in patients with Parkinson’s disease
Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…Effect of the MAO-B inhibitor and glutamate modulator safinamide on depressive symptoms in three Parkinson’s disease patients
Objective: Patients suffering from Parkinson’s disease experience various motor and non-motor symptoms. Within the range of non-motor symptoms depression is reported as high as in…Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations
Objective: To evaluate the potential added benefit of opicapone (OPC), compared with placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients…The influence of ANNK1/DRD2 haplotypes on the onset of complications of long-term levodopa therapy in Parkinson’s disease
Objective: To investigate an influence of selected polymorphisms in DRD2 and ANKK1 genes on the occurrence of complications of long-term levodopa therapy in Serbian PD…Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease
Objective: Our goal is to develop small molecules which support and restore nigrostriatal dopamine neurons by activation of glial cell line-derived-neurotrophic factor (GDNF) receptors. Background:…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 149
- Next Page »